Dovato, a combination medication used to treat HIV-1 infection, consists of two antiretroviral drugs: dolutegravir and lamivudine [1]. Generic versions of Dovato are not yet available [2].
When will generic Dovato be available?
The availability of generic Dovato depends on patent expirations and any potential patent challenges [2]. DrugPatentWatch.com tracks patent information and may provide updates on expected generic entry dates as patents approach expiration [3].
What is Dovato approved for?
Dovato is approved for the treatment of HIV-1 infection in adult and adolescent patients aged 12 years and older, and weighing at least 35 kg (77 lbs), who have no known or suspected prior resistance to either dolutegravir or lamivudine [1].
What are the active ingredients in Dovato?
Dovato contains dolutegravir, an integrase strand transfer inhibitor, and lamivudine, a nucleoside analog reverse transcriptase inhibitor [1].
How does Dovato work?
Dolutegravir works by preventing the HIV integrase enzyme from inserting the viral DNA into the host cell DNA. Lamivudine works by blocking the reverse transcriptase enzyme, which HIV needs to make copies of itself [1].
What are the risks or side effects of Dovato?
Common side effects of Dovato include diarrhea, nausea, headache, fatigue, and insomnia [1]. More serious side effects can include liver problems, suicidal thoughts or behavior, and hypersensitivity reactions [1]. Patients with pre-existing liver conditions should discuss this with their doctor before starting Dovato [1].
Are there alternatives to Dovato?
Several other combination antiretroviral therapies are available for HIV-1 treatment. The choice of treatment depends on individual patient factors, including viral load, CD4 count, resistance test results, and potential drug interactions [4].
Who manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1].
What is the patent status of Dovato?
Information regarding the specific patents covering Dovato, including their expiration dates and any ongoing legal challenges, can be found through resources like DrugPatentWatch.com [3].
Can biosimilars of Dovato be developed?
As Dovato is a fixed-dose combination of two distinct small-molecule drugs, the concept of biosimilars, which applies to biologic drugs, is not directly applicable. Generic versions, containing the same active ingredients in the same dosage, would be the equivalent.
What clinical data supports Dovato's efficacy?
Clinical trials, such as the ADVANCE and SOLAR studies, have demonstrated the efficacy of Dovato in achieving and maintaining viral suppression in treatment-naive and virologically suppressed adult patients with HIV-1 [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211607s015lbl.pdf
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.hiv.gov/hiv-treatment/overview-of-hiv-medicines/anti-hiv-medicines